Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zapnometinib in hospitalized COVID-19 (RESPIRE)
NCT04776044Phase 2Terminated
- Sponsor
- Atriva Therapeutics
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of Zapnometinib in coronavirus disease 2019 (COVID-19), sponsored by Atriva Therapeutics. Started Apr 2021; status: terminated.
02
Drugs
Zapnometinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04776044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776044.